Curated News
By: NewsRamp Editorial Staff
May 12, 2026

Lantern Pharma to Report Q1 2026 Results, Updates AI Pipeline

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Lantern Pharma to report Q1 2026 results on May 15, offering investors key insights into AI-driven oncology progress.
  • Lantern Pharma uses AI and RADR platform to develop cancer therapies, with pipeline including LP-184, LP-284, and LP-300.
  • Lantern Pharma's AI-driven precision oncology aims to improve cancer treatment, with a CNS-focused subsidiary for pediatric brain cancers.
  • Lantern Pharma's withZeta.ai platform is now commercially available as a subscription for biomedical research.

Impact - Why it Matters

This news matters because it provides a glimpse into the progress of an AI-driven oncology company that is using machine learning to accelerate drug development. For investors and patients, Lantern Pharma's upcoming earnings release could signal advancements in precision oncology, including clinical trial updates for its pipeline drugs and the commercial traction of its withZeta.ai platform. The company's focus on AI and rare cancers (like pediatric CNS tumors) underscores a shift toward more targeted, data-driven therapies. If successful, Lantern's approach could reduce drug development costs and time, potentially bringing new treatments to market faster for underserved patient populations.

Summary

Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced that it will report its first-quarter 2026 operating and financial results via press release on May 15. The update will include financial results for the quarter ended March 31, 2026, along with operational updates regarding the company’s clinical trials and development of its proprietary artificial intelligence and machine learning platforms. This announcement highlights Lantern’s continued progress in leveraging AI to transform cancer therapy development.

Lantern Pharma’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. Notably, withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.

This news was disseminated by MissionIR, a specialized communications platform that assists IR firms with syndicated content. MissionIR is part of the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For investors, the latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma to Report Q1 2026 Results, Updates AI Pipeline

blockchain registration record for this content.